Advertisement


Mark Saunders, MD, PhD, on Colorectal Cancer: Results From the SCOT Trial

2018 Gastrointestinal Cancers Symposium

Advertisement

Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).



Related Videos

Pancreatic Cancer

Ramesh K. Ramanathan, MD, on Metastatic Pancreatic Cancer: Results From a SWOG Study

Ramesh K. Ramanathan, MD, of the Mayo Clinic, discusses early-phase study findings on mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase vs mFFOX alone in patients with a good performance status (Abstract 208).

Gastroesophageal Cancer
Gastrointestinal Cancer

Maria Svensson, MD, PhD Candidate, on Esophageal and Gastric Cancers: Significance of PD-1 and PD-L1 Expression

Maria Svensson, MD, PhD Candidate, of Lund University, discusses high expression of PD-1 and PD-L1 in chemotherapy-naive esophageal and gastric adenocarcinomas, the implications for survival, and the link to a deficiency in mismatched repair genes (Abstract 9).

Gastroesophageal Cancer
Gastrointestinal Cancer

Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial

Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).

Gastroesophageal Cancer

Pieter van der Sluis, MD, PhD, on Esophageal Cancer: Results From a Surgical Treatment Trial

Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy vs open transthoracic esophagectomy for resectable esophageal cancer (Abstract 6).

Gastroesophageal Cancer

David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.

Advertisement

Advertisement



Advertisement